PUT - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 07:53:19 2024-05-29 am EDT | ||
| 2.92 EUR | +3.18% |
|
| Current month | -4.71% | ||
| 1 month | -9.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 2.92 | +3.18% |
| 24-05-28 | 2.83 | +5.99% |
| 24-05-27 | 2.67 | +6.37% |
| 24-05-24 | 2.51 | +2.45% |
| 24-05-23 | 2.45 | -8.92% |
Real-time Boerse Frankfurt Warrants
Last update May 29, 2024 at 07:53 am EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAY |
| ISIN | DE000VD1XAY9 |
| Date issued | 2024-03-08 |
| Strike | 1,126 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.06 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.88 € |
|---|---|
| Lowest since issue | 2.45 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
